Metrics to compare | OBI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOBIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | −2.4x | −0.5x | |
PEG Ratio | −5.18 | −0.15 | 0.00 | |
Price/Book | 155.1x | 2.1x | 2.6x | |
Price / LTM Sales | 51.1x | 5.9x | 3.3x | |
Upside (Analyst Target) | 368.1% | 212.5% | 47.1% | |
Fair Value Upside | Unlock | 3.7% | 6.2% | Unlock |
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.